Vitamin D’s Cardiac Promise Fades Under Trial Pressure

Key Takeaway: The TARGET-D trial randomized 630 patients who had suffered a heart attack to either targeted vitamin D supplementation or standard care and found no significant reduction in major adverse cardiovascular events. While a secondary analysis hinted at a decrease in recurrent heart attacks, the study was not designed to confirm this finding. This primary outcome adds to a growing body of evidence suggesting that vitamin D is not the cardiovascular magic bullet many had hoped for.

The Undying Hypothesis

For more than two decades, the story seemed almost perfect: individuals with low vitamin D levels had higher rates of heart attack, stroke, and death from cardiovascular causes. One observational study after another drew a tantalizing link between this “sunshine deficiency” in blood levels and cardiac catastrophe. The logic was seductive—if low vitamin D is associated with poor outcomes, then raising the level should fix the problem. But medicine has been burned by this reasoning before, most famously with hormone replacement therapy and beta-carotene, where promising observational findings were crushed under the weight of randomized evidence^[2]. Now, the TARGET-D trial delivers another sober lesson that association is not the same as causation, even when we badly want it to be.

What the Researchers Did

The TARGET-D was a pragmatic, randomized controlled trial involving 630 patients who had recently experienced a myocardial infarction—a heart attack. Participants were split into two groups: one received standard post-heart attack therapy, while the other received vitamin D3 supplementation specifically dosed to maintain their blood levels between 40 and 80 ng/mL. This is a critical design detail. Previous large-scale trials, including the landmark VITAL trial with over 25,000 participants, used fixed daily doses of vitamin D regardless of baseline levels^[3]. TARGET-D took a more aggressive and personalized approach—measuring blood levels and adjusting doses to hit a specific target range. If any vitamin D strategy were to work, this targeted method was expected to give it the best possible chance.

The primary endpoint was a composite of major adverse cardiovascular events (MACE)—a standard metric that combines cardiovascular death, nonfatal heart attack, nonfatal stroke, and hospitalization for heart failure into a single outcome.

The Findings

The study’s main result was clear: targeted vitamin D supplementation did not significantly reduce the rate of MACE. The composite endpoint occurred in 15.7% of the supplementation group versus 18.4% of the standard care group—a result with a hazard ratio of 0.85 and a p-value of 0.40, well outside the threshold for statistical significance^[1]. There were no significant differences between the two groups in the rates of death, hospitalization for heart failure, or stroke.

There was one secondary finding that caught the eye: recurrent heart attack occurred in 3.8% of the vitamin D group versus 7.9% in the standard care group, yielding a hazard ratio of 0.48 and a p-value of 0.03. At first glance, that’s a striking number—a nearly fifty percent reduction in risk. But context here is crucial. The study enrolled 630 patients and was powered to detect differences in the composite MACE endpoint, not its individual components. When you test multiple secondary endpoints in a moderately sized trial, some may cross statistical thresholds by chance alone. This finding is, at best, hypothesis-generating—it’s a signal worth exploring in a larger, dedicated trial, not a reason to change practice.

Mechanism: Why Vitamin D Might Protect the Heart — and Why It Might Not

The biological rationale for a cardiovascular role for vitamin D is not unreasonable. Vitamin D receptors are expressed throughout the cardiovascular system in cardiomyocytes, vascular smooth muscle cells, and endothelial cells^[4]. In laboratory models, calcitriol, the active form of vitamin D, can modulate the renin-angiotensin-aldosterone system, a hormonal cascade that governs blood pressure, fluid balance, and cardiac remodeling after injury^[5]. Vitamin D can also influence inflammatory pathways by suppressing pro-inflammatory cytokines like interleukin-6 and tumor necrosis factor-alpha, both of which are elevated after a heart attack and contribute to ongoing vascular damage.

So why doesn’t correcting a deficiency translate into fewer events? One possibility is confounding. Low vitamin D levels are strongly associated with independent cardiovascular risk factors like obesity, a sedentary lifestyle, chronic kidney disease, and older age^[6]. Observational studies may be measuring the shadow of these conditions rather than a direct effect of vitamin D. Another possibility is one of timing and effect size: the biological effects of vitamin D on vascular inflammation and remodeling, while real in a culture dish, may be too modest to make a meaningful difference in patients who are already receiving modern post-MI therapies—dual antiplatelet agents, high-intensity statins, beta-blockers, and ACE inhibitors. Against this pharmacological backdrop, the marginal contribution of normalized vitamin D levels may be clinically invisible.

Notable Limitations

No single study settles a question permanently, and TARGET-D has important limitations. At 630 patients, it was modestly sized; a larger trial could have detected a smaller but real benefit—or confirmed the null finding with greater certainty. The follow-up period, while adequate for a MACE endpoint, may not capture the very long-term effects of vitamin D optimization. Furthermore, its pragmatic design, while enhancing real-world applicability, introduces variability in adherence and concomitant therapies that a more tightly controlled efficacy trial would minimize.

The Verdict: What These Results Mean for the Future

For the cardiologist facing a patient recovering from a heart attack, TARGET-D delivers a clear practical message: prescribing vitamin D supplementation with the goal of preventing future cardiovascular events is not supported by this evidence. The targeted strategy, arguably the most rigorous vitamin D intervention tested in this population, failed to reduce the composite of death, recurrent heart attack, stroke, and heart failure hospitalization. The intriguing signal in recurrent MI warrants further investigation, but to use it as a rationale for routine supplementation would be both premature and potentially misleading.

This doesn’t mean vitamin D is useless. It remains essential for bone health, calcium metabolism, and immune function, and patients with documented deficiency should still be treated for those indications. But the cardiovascular fairy tale—the idea that a simple, inexpensive supplement could meaningfully reduce heart attacks and strokes—continues to lack the randomized evidence it needs. Sometimes, the most important thing a clinical trial can tell us is what *doesn’t* work, so we can focus our energy—and our patients’ trust—on the treatments that do.

Scientific Sources

1. May HT, et al. Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial. European heart journal. 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42702500/
2. Lawlor DA, et al. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet. 2004. DOI: 10.1016/S0140-6736(04)16260-0
3. Manson JE, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019. DOI: 10.1056/NEJMoa1809944
4. Norman PE, et al. Vitamin D and cardiovascular disease. Circ Res. 2014. DOI: 10.1161/CIRCRESAHA.113.301241
5. Li YC, et al. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004. DOI: 10.1016/j.jsbmb.2004.03.004
6. Autier P, et al. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014. DOI: 10.1016/S2213-8587(13)70165-7